Catheter Precision, Inc. (VTAK) Stock

Catheter Precision, Inc. (VTAK) is a Healthcare stock trading at $0.20 (as of 2026-08-20), with a market capitalization of $4.03M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Catheter Precision, Inc. develops and sells electrophysiology products, including the View into Ventricular Onset System for non-invasive 3D cardiac mapping to localize the origin sites of idiopathic ventricular arrhythmias prior to electrophysiology procedures, along with LockeT and the Amigo Remote Catheter System. Its products are used by patients, hospitals, and physicians in the United States.

Understand Catheter Precision, Inc.: how it makes money

Catheter Precision develops electrophysiology medical devices, including its non-invasive View into Ventricular Onset System for 3D cardiac mapping, and sells these products to patients, hospitals, and physicians in the United States.

The profit model is largely about selling electrophysiology tools used in EP procedures (diagnosis and procedural support) while maintaining product-level gross profit, but the latest quarter shows gross margin (90.3%) that was more than offset by very high operating losses (operating margin -536.6%).

Business quality (Weak): High product gross margin, but profitability is currently weak with a deeply negative operating margin in the latest reported quarter.

Bull case

  • Procedure-focused product positioning: Its lead View into Ventricular Onset System provides 3D cardiac mapping to help localize the sites of origin of idiopathic ventricular arrhythmias prior to EP procedures.
  • Broad electrophysiology product set: It also provides LockeT (suture retention device) and the Amigo Remote Catheter System, expanding beyond a single imaging tool.

Bear case

  • Operating losses are substantial: The latest quarter shows an operating margin of -536.6%, indicating operating costs are far above gross profit.
  • Adoption depends on clinical use in US EP workflows: Its products are used by hospitals and physicians in the United States for cardiac arrhythmia care, so outcomes depend on uptake and sustained use in those settings.
Valuation — source: SEC EDGAR (first-party)
Price$0.20
Market Cap$4.03M
EV / EBITDA-0.8
Price / Book0.24
Price / Sales2.10
FCF Yield-232.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$819000.00
Net Margin-2098.0%
Return on Equity-75.9%
Debt / Equity0.56
Current Ratio0.19
Revenue Growth (YoY)95.0%
EPS Growth (YoY)138.0%
FCF Growth (YoY)-11.0%
Financial Health — source: SEC EDGAR
Altman Z-Score-31.90 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGEODE CAPITAL MANAGEMENT, LLC ($48135.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEODavid A. Jenkins
Employees22
CountryUS
IPO Date2018-09-27

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Intelligent Bio Solutions Inc. (INBS)
  • Co-Diagnostics, Inc. (CODX)
  • enVVeno Medical Corporation (NVNO)
  • Picard Medical, Inc. (PMI)
  • Autonomix Medical, Inc. Common Stock (AMIX)
  • Bluejay Diagnostics, Inc. (BJDX)
  • Sonoma Pharmaceuticals, Inc. (SNOA)
  • Amundi Core MSCI Emerging Markets UCITS ETF EUR Dist (AEMD)
VTAK earnings history · VTAK institutional & insider holders · VTAK KPIs & operating metrics · VTAK financials · VTAK investor presentations & press releases · VTAK SEC filings · VTAK peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.